Massachusetts crossed $10B in adult-use cannabis sales, signaling durable demand—and a wake-up call for delivery operators, investors, and app builders planning their next move.

Explore how employer-sponsored medical cannabis benefits are cutting healthcare costs, backed by clinical research and DMV access updates.

A new study reveals that cannabigerol (CBG) preserved long-term memory in animal models using an unexpected molecular pathway.

Consumer demand and evolving product design make blunts a ripe segment. Here’s how brands, retailers, and delivery operators can approach compliance and scale in the DMV.

A new federal survey highlighted by NORML shows youth cannabis use continuing to fall. Here’s what the trend means for DMV policy, delivery compliance, and prevention.

A clear, step-by-step 2026 guide to spotting healthy cannabis seeds, planning your grow timeline, and sourcing wisely—plus DMV business angles and risks to watch.

A sophisticated RFP-themed phishing campaign is hitting cannabis companies. Here’s how delivery operators, investors, and DMV entrepreneurs can protect revenue and assess risk now.

People seek ways to pause a difficult psychedelic experience. Psychedelic Science Review spotlights ketanserin’s promise. Here’s what’s known, what isn’t, and harm-reduction context for DMV readers.

NORML reports an association between medical cannabis access laws and gains in workplace productivity and innovation. Here’s what that could mean for DMV residents and delivery compliance.

An Arizona-based MSO paused operations at an Ohio cannabis store after state regulators began investigating at least two serious adverse health events tied to suspected customers.

Congress pushed back the federal hemp-derived cannabinoid deadline to Dec. 11. Here’s how DMV operators and consumers can prepare without guessing what Washington will do.

Two federal marijuana sentences were cut as Washington debates moving some cannabis to Schedule III. Here’s what’s known now—and what DMV residents should watch.

Definium Therapeutics reports Phase 3 topline success for LSD (DT120) in generalized anxiety disorder, following MDD progress. Here’s the clinical context and what DMV patients should watch.

MJBizDaily reports Endovia is seeking FDA veterinary approval for a cannabinoid drug aimed at canine cancer and chronic pain—an R&D path that could reshape investor focus.

Highlandia’s Rocket Peak took Best in Show as the hemp-derived THC beverage brand collected four medals at the 2026 Summer PR%F Awards, signaling buyer interest ahead.

High Times columnist Ed Rosenthal argues India’s 1986 cannabis criminalization, rooted in a 1961 UN treaty, should be reversed—here’s why it matters.

Clinical trial momentum has regulators eyeing MDMA and psilocybin. Here’s how “abuse potential” factors into rescheduling talks—and what DMV readers should watch.

NORML reports a pediatric clinical trial found a plant-derived cannabis preparation was safe and effective for autism, with disease severity falling about 2 points on a 7‑point scale after eight weeks.

What science says about terpenes, how they shape cannabis effects with cannabinoids, and what this means for patients and consumers in DC, Maryland and Virginia.

An executive order in Puerto Rico directs health officials to build a pilot program for ibogaine, psilocybin, and MDMA research, with veterans prioritized for potential clinical trial access.